1 to 7 of 7 literature results

• Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens.

  Desmoplastic melanoma is a diagnostic and therapeutic challenge. Immunohistochemical analysis with antibodies to melanoma antigens can complement morp…

  Authors: Elgene Lim, Judy Browning, Duncan MacGregor, Ian D Davis, Jonathan S Cebon

  Source: Melanoma research. 2006 Aug

  View Full Text

• Predicting clinical outcome through molecular profiling in stage III melanoma.

  PURPOSE: Patients with macroscopic stage III melanoma represent a heterogeneous cohort with average 5-year overall survival rates of <30%. With curren…

  Authors: Thomas John, Michael A Black, Tumi T Toro, Debbie Leader, Craig A Gedye, Ian D Davis, Parry J Guilford, Jonathan S Cebon

  Source: Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Aug 15

  View Full Text

• Impact of 2-deoxy-2[F-18]fluoro-D-glucose Positron Emission Tomography on the management of patients with advanced melanoma.

  OBJECTIVES: Accurate staging of patients with melanoma is vital to guide appropriate treatment. 2-Deoxy-2-[F-18]fluoro-D-glucose (FDG)-positron emissi…

  Authors: Marion T Harris, Salvatore U Berlangieri, Jonathan S Cebon, Ian D Davis, Andrew M Scott

  Source: Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging. 2005 Jul-Aug

  View Full Text

• ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer.

  PURPOSE: Cancer cells recapitulate many behaviors of pluripotent embryonic cells such as unlimited proliferation, and the capacity to self-renew and t…

  Authors: Thomas John, Otavia L Caballero, Suzanne J Svobodová, Alan Kong, Ramon Chua, Judy Browning, Sheila Fortunato, Siddhartha Deb, Melinda Hsu, Craig A Gedye,…

  Source: Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Jun 1

  View Full Text

• A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake.

  PURPOSE: To determine the in vivo characteristics of huA33, a CDR-grafted humanized antibody against the A33 antigen, we have conducted an open-label,…

  Authors: Andrew M Scott, Fook-Thean Lee, Robert Jones, Wendie Hopkins, Duncan MacGregor, Jonathan S Cebon, Anthony Hannah, Geoffrey Chong, Paul U, Anthony Papenfuss,…

  Source: Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Jul 1

  View Full Text

• Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.

  PURPOSE: Humanized monoclonal antibody A33 (huA33) targets the A33 antigen which is expressed on 95% of colorectal cancers. A previous study has shown…

  Authors: Geoffrey Chong, Fook Thean Lee, Wendie Hopkins, Niall Tebbutt, Jonathan S Cebon, Angela J Mountain, Bridget Chappell, Anthony Papenfuss, Paul Schleyer, Paul U,…

  Source: Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Jul 1

  View Full Text

• Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.

  NY-ESO-1 is a "cancer-testis" antigen expressed in many cancers. ISCOMATRIX is a saponin-based adjuvant that induces antibody and T cell responses. We…

  Authors: Ian D Davis, Weisan Chen, Heather Jackson, Phillip Parente, Mark Shackleton, Wendie Hopkins, Qiyuan Chen, Nektaria Dimopoulos, Tina Luke, Roger Murphy,…

  Source: Proceedings of the National Academy of Sciences of the United States of America. 2004 Jul 20

  View Free Full Text